Skip To Main Content
Aaron M Drucker on Muck Rack

Aaron M Drucker

As seen in: Allergy - European Journal of Allergy and Clinical Immunology, Color Research & Application, Wiley Online Library, Memory Studies, JAMA (The Journal of the American Medical Association), JAMA Dermatology, JAMA: Journal of the American Medical Association, The Lancet, Annals of Internal Medicine, Canadian Medical Association Journal and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Aaron M

Contact Aaron M, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

VIDEO: Risk for developing atopic dermatitis often genetic, but sometimes modifiable

|
By Aaron M Drucker, Erin Theresa Verified
| Healio Dermatology Verified
Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription. I'm Aaron Drucker. I'm an associate professor in the Department of Medicine at the University of Toronto and a dermatologist and clinician scientist at Sunnybrook Health Sciences Centre. We know that most of the risk for atopic dermatitis is genetic, and there's not much people can do about that, of course.
Open in Who Shared Issue with article?

VIDEO: More phase 3, comparative treatment data can help inform atopic dermatitis care

|
By Aaron M Drucker, Erin Theresa Verified
| Healio Dermatology Verified
Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription. I'm always excited for new data on new treatments and old treatments. Anytime we get really excited about a new potential molecule that we see phase 1 and phase 2 data for, we need that big phase 3 data.
Open in Who Shared Issue with article?

VIDEO: Expert ‘looking forward’ to new biologics for atopic dermatitis

|
By Aaron M Drucker, Erin Theresa Verified
| Healio Dermatology Verified
Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription. The pipeline for atopic dermatitis are a number of different biologic and small molecule agents. We've had a few biologics approved since 2017 when dupilumab (Dupixent; Sanofi, Regeneron) was approved and also oral JAK inhibitors, and there have been a few approved since then.
Open in Who Shared Issue with article?
See all 54 licensed articles (57 Total)